

# AGM Voting

RNS Number : 6187H

Novacyt S.A.

10 June 2026

**Novacyt S.A.**

**("Novacyt", the "Company" or the "Group")**

## **AGM Voting**

**Paris, France, and Manchester, UK - 10 June 2026** - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, confirms it will be holding its Annual General Meeting ("AGM") at 11am CEST/10am BST on Tuesday, 30 June 2026 at the Hilton Hotel, Charles de Gaulle Airport, 8 Rue de Rome, 93290 Tremblay-en-France, France. As usual, and in accordance with French corporate law, the AGM comprises both ordinary and extraordinary resolutions. All materials can be found at [www.novacyt.com/investors](http://www.novacyt.com/investors).

Shareholders are strongly encouraged to submit their votes in advance, in accordance with the instructions in the Notice of the AGM.

Under French law, for the AGM and EGM meetings to be quorate at the first attempt, shareholders representing at least 20% of the share capital and voting rights, on ordinary resolutions, and 25% of the share capital and voting rights, on extraordinary resolutions, must be present, represented or have voted in advance under the conditions set out below.

Shareholders can vote in advance of the AGM by:

- Downloading a copy of the proxy voting form from the website [www.novacyt.com/investors](http://www.novacyt.com/investors), completing it and returning it together with evidence of their shareholding which must be in the form of a share certificate (attestation), either by post to the following address: 6 avenue de Provence 75452 Paris Cedex 09, or via email to the following address: [serviceproxy@cic.fr](mailto:serviceproxy@cic.fr), or [investor.relations@novacyt.com](mailto:investor.relations@novacyt.com), no later than 26 June 2026 inclusive.

- Voting on-line using the Votaccess portal <http://www.actionnaire.cic-marketsolutions.eu> if securities held on Euronext Growth are registered with any of the following banks: CIC, Natixis, Société Générale, Caceis, Crédit Agricole, BP2S, BNP Retail, Bourse Direct, ODDO, Rothschild Martin Maurel, Procapital, Citibank, Deutsche Bank, Bank of New York or JP Morgan. The Votaccess portal will be open from 8 June 2026 to 29 June 2026 at 2pm

BST/3pm CEST.

- Voting on-line via a broker, nominee, bank or authorised intermediary. Many intermediaries in the UK such as Hargreaves Lansdown are now using the Broadridge ProxyVote on-line voting portal.

Participation in the AGM is confined to shareholders who can prove that their shares are registered in their name or in the name of the intermediary registered on their behalf by the fifth business day prior to the AGM, **i.e.**

**23 June 2026 at zero-hour, Paris time (22 June 2026 at 11pm BST ):**

- either in the registered securities accounts kept by the company, or
- in bearer securities accounts kept by the authorised intermediary.

Shareholders wishing to attend the AGM in person may:

- For shareholders whose shares are registered with CIC: present themselves on the day of the Annual General Meeting, with proof of identity.
- Shareholders whose shares are registered in bearer form: ask the authorised intermediary who manages their securities account to send them a proof of shareholding or a letter of representation, evidencing that they hold shares of Novacyt.

Shareholders can also request an admission card in advance (a) from CIC Services, by post to the following address: CIC Services Assemblées Générales, 6 avenue de Provence 75452 Paris Cedex 09, or by email to the following address: [serviceproxy@cic.fr](mailto:serviceproxy@cic.fr); or (b) on the secure VOTACCESS platform accessible via the website <https://www.actionnaire.cic-marketsolutions.eu>.

Shareholders who have already voted (through a proxy, via their broker, nominee, bank, authorised intermediary, Votaccess portal or Broadridge ProxyVote) will be allowed to attend the AGM but will not be able to vote twice.

An investor presentation by Lyn Rees, Chief Executive Officer, and Steve Gibson, Chief Financial Officer, will be made available on the Company's website and via the Investor Meet Company platform on the day of the meeting, which will include automated French subtitling.

Investors can sign up for the webinar via: <https://www.investormeetcompany.com/novacyt-sa/register-investor>

Investors who already follow NOVACYT S.A. on the Investor Meet Company platform will automatically be invited.

## Contacts

<b>Novacyt SA</b>	<a href="https://novacyt.com/investors">https://novacyt.com/investors</a>
Lyn Rees, Chief Executive Officer	<b>Via Walbrook PR</b>
Steve Gibson, Chief Financial Officer	
<b>SP Angel Corporate Finance LLP (Nominated Adviser and Broker)</b>	+44 (0)20 3470 0470
Matthew Johnson / Charlie Bouverat (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking)	
<b>Singer Capital Markets (Joint Broker)</b>	+44 (0) 20 7496 3000
Phil Davies / James Fischer / Samed Ethem	
<b>Allegra Finance (French Listing Sponsor)</b> Rémi Durgetto / Yannick Petit	+33 (1) 42 22 10 10 r.durgetto@allegrafinance.com / y.petit@allegrafinance.com
<b>Walbrook PR (Financial PR &amp; IR)</b> Paul McManus / Lianne Applegarth Alice Woodings	+44 (0)20 7933 8780 or novacyt@walbrookpr.com +44 (0)7980 541 893 / +44 (0)7584 391 303 +44 (0)7407 804 654

NOVACYT  
GROUP

An international molecular diagnostics company,  
providing a broad portfolio of clinical and research  
use only products, and instrumentation

PRIMER  
DESIGN

Yourgene  
Health

SCD  
SOUTHERN CROSS  
DIAGNOSTICS

### About Novacyt Group ([www.novacyt.com](http://www.novacyt.com))

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

<b>Clinical</b>	<p>Broad portfolio of human clinical <i>in vitro</i> diagnostic products, workflows and services focused on three therapeutic areas:</p> <ul style="list-style-type: none"><li>· Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests</li><li>· Precision Medicine: DPYD genotyping assay</li><li>· Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel</li></ul>
<b>Instrumentation</b>	<p>Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:</p> <ul style="list-style-type: none"><li>· Ranger® Technology: automated DNA sample preparation and target enrichment technology</li><li>· genesig q16 and q32 real-time quantitative PCR (qPCR) instruments</li></ul>
<b>Research Use Only</b>	<p>Range of services for the life sciences industry:</p> <ul style="list-style-type: none"><li>· Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry</li><li>· Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)</li></ul>

Novacyt is headquartered in Le Vésinet in France with offices in the UK (Manchester), Singapore, the US and Canada and has a commercial presence in over 65 countries, including Australia, following the recent acquisition of Southern Cross Diagnostics in March 2026, which has opened new distribution channels to the life sciences and diagnostics industries in the territory and the wider Asia-Pacific region.

The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: [www.novacyt.com](http://www.novacyt.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com). RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOAFLFVLRTIAIR